Structure's Oral Drug Heats Up Crowded Obesity Market Race

SAN FRANCISCO, CA – February 26, 2026 – Structure Therapeutics has emerged as a formidable contender in the high-stakes race for oral obesity treatments, reporting strong late-stage clinical data for its lead candidate, aleniglipron. The announcement, part of its 2025 year-end financial results, detailed significant weight loss in patients and outlined an aggressive path toward a pivotal Phase 3 trial, all backed by a formidable $1.4 billion war chest.

The news positions the clinical-stage biopharmaceutical company to challenge established giants and other agile biotechs vying for a share of a market projected to exceed $100 billion by 2030. With patients and physicians increasingly seeking convenient alternatives to injectable drugs, Structure's focus on oral small molecules could prove to be a decisive strategic advantage.

"The obesity market is clearly embracing the introduction of new oral treatment options and Structure Therapeutics is well positioned to capture market share in this important therapeutic area,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics, in the company's official statement.

The Quest for a Pill-Based Powerhouse

The centerpiece of Structure's update is aleniglipron, an oral small molecule designed to activate the GLP-1 receptor, the same biological target as blockbuster injectable drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The company reported compelling 36-week data from its Phase 2b ACCESS program, showing that higher doses of the drug led to a placebo-adjusted mean weight loss of up to 15.3%.

Crucially, the company noted that no plateau in weight loss was observed at the 36-week mark, suggesting further benefits may be seen with longer treatment. These results place aleniglipron squarely in competition with other oral GLP-1 candidates. For context, Pfizer’s twice-daily oral drug, danuglipron, showed placebo-adjusted weight loss between 8% and 13% at 32 weeks, though it was hampered by high rates of side effects. Eli Lilly’s oral contender, orforglipron, has also shown significant weight loss but with its own tolerability challenges.

Structure appears focused on addressing the tolerability issues that have plagued some competitors. The company highlighted that in studies utilizing a new, lower starting dose of 2.5 mg, no patients discontinued treatment due to adverse events. This focus on a manageable side effect profile could be a key differentiator in a market where long-term adherence is critical for success. The company expects to release even more mature, 44-week data from its higher-dose ACCESS II study in the first quarter of 2026, which will provide a more complete picture of aleniglipron's potential ahead of its move into the final stage of clinical testing.

Charting a Course Through Regulation

With promising Phase 2 data in hand, Structure Therapeutics is now preparing to navigate the rigorous and expensive path to regulatory approval. The company plans to meet with the U.S. Food and Drug Administration (FDA) for an End-of-Phase 2 meeting to finalize the design of its Phase 3 registrational program, which it anticipates initiating in the second half of 2026.

This process will be guided by the FDA's updated 2025 guidance, which officially recognizes obesity as a chronic disease and sets a high bar for new treatments. Regulators now expect to see data from trials lasting over a year that demonstrate a sustained and clinically meaningful weight reduction of at least 5% over a placebo. Structure's ongoing supplementary studies—evaluating body composition, use in patients with type 2 diabetes, and the transition from injectable GLP-1s—appear designed to build the comprehensive data package the FDA will demand.

These studies demonstrate a proactive strategy to define aleniglipron's profile not just as a primary weight loss agent, but also as a potential maintenance therapy and an option for diverse patient populations, strengthening its case for broad market access upon potential approval.

Beyond GLP-1: A Diversified Bet on the Future

While aleniglipron is its most advanced asset, Structure Therapeutics is also making a strategic bet on the next wave of obesity treatments that go beyond the GLP-1 mechanism. The company's pipeline includes two oral small molecule amylin receptor agonists, ACCG-2671 and ACCG-3535, positioning it at the forefront of another promising biological pathway for weight management.

Amylin is a hormone that works alongside GLP-1 to regulate appetite and glucose. The combination of these mechanisms has shown even greater weight loss in clinical trials, as seen with Novo Nordisk's injectable combination drug candidate, CagriSema. However, most amylin-based therapies in development by competitors are injectable.

Structure's claim that its candidate, ACCG-2671, is the "industry’s most advanced oral small molecule amylin therapy" underscores its unique approach. By developing a pill-based version, Structure could potentially offer the first convenient, oral combination therapies, either by co-formulating its own drugs or by positioning its amylin agonist as an add-on to existing GLP-1 treatments. Initial data from the Phase 1 study of ACCG-2671 and the initiation of a Phase 1 study for the second-generation compound ACCG-3535 are both expected in the second half of 2026, marking another series of key catalysts for the company.

Financial Firepower for a Protracted Battle

Underpinning these ambitious clinical and regulatory plans is an exceptionally strong balance sheet. Structure Therapeutics ended 2025 with $1.4 billion in cash, cash equivalents, and short-term investments. The company projects this cash runway will be sufficient to fund its operations and key clinical milestones, including the costly Phase 3 program for aleniglipron, through the end of 2028.

This financial firepower is a critical advantage in the capital-intensive biopharmaceutical industry. It insulates the company from market volatility and reduces the immediate need for dilutive financing, allowing management to execute its long-term strategy from a position of strength. While the company reported a net loss of $141.2 million for the full year 2025, its fourth quarter was notably profitable, boosted by $100 million in licensing income and over $10 million from an asset sale.

With promising data, a diversified next-generation pipeline, and the financial resources to fuel its journey, Structure Therapeutics has solidified its status as a company to watch. The path forward is fraught with competitive and regulatory hurdles, but the firm has assembled the key ingredients needed to compete in the transformative and lucrative field of metabolic disease treatment.